🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

12 recruiting trials

for Myelosuppression

Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma NCT07819656n/a1 site📍 Guangzhou Nanfang Hospital, Southern Medical University UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia NCT06245746Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo) Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC) NCT06992739Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib and Sacituzumab Tirumotecan Study of Trilaciclib and Lurbinectidin NCT05578326Phase 22 sites📍 Lebanon📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Trilaciclib, Lurbinectedin Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy NCT06589089Phase 21 site📍 Shanghai Ruijin Hospital · Tests: autologous hematopoietic stem cell Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib NCT06699472Phase 21 site📍 Shanghai Fudan University · Tests: Chemotherapy, Trilaciclib Injection [Cosela] A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients NCT07578064Phase 41 site📍 Shanghai Hongxia Wang · Tests: Group A, Group B Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment NCT07477119Phase 41 site📍 Conakry Marco Schiuma · Tests: Linezolid dose personalization based on TDM Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma NCT06698692n/a1 site📍 Nanjing The First Affiliated Hospital with Nanjing Medical Universi… · Tests: Trilaciclib Injection [Cosela] Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin NCT06698965Phase 21 site📍 Shanghai Shanghai Chest Hospital · Tests: Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy NCT07205536Phase 21 site📍 Nantong Affiliated Hospital of Nantong University · Tests: Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy